These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10928306)

  • 21. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance.
    Altamura AC
    Schizophr Res; 1993 Jan; 8(3):187-98. PubMed ID: 8094628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients.
    Chouinard G; Annable L; Kropsky M
    J Clin Pharmacol; 1978; 18(2-3):148-54. PubMed ID: 24061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
    Wiles DH; McCreadie RG; Whitehead A
    Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative trail of fluphenazine decanoate and flupenthixol decanoate.
    Haslam MT; Bromham BM; Schiff AA
    Acta Psychiatr Scand; 1975 Feb; 51(2):92-100. PubMed ID: 1091124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate.
    Schooler NR; Levine J; Severe JB; Brauzer B; DiMascio A; Klerman GL; Tuason VB
    Arch Gen Psychiatry; 1980 Jan; 37(1):16-24. PubMed ID: 7352836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs.
    Mauri MC; Moliterno D; Rossattini M; Colasanti A
    Schizophr Res; 2008 Feb; 99(1-3):7-12. PubMed ID: 18055177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of fluphenazine plasma levels versus clinical response in patients: a pilot study.
    Dudley J; Rauw G; Hawes EM; Keegan DL; Midha KK
    Prog Neuropsychopharmacol Biol Psychiatry; 1983; 7(4-6):791-5. PubMed ID: 6686710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
    Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
    Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical implications of increased antipsychotic plasma concentrations upon anticonvulsant cessation.
    Jann MW; Fidone GS; Hernandez JM; Amrung S; Davis CM
    Psychiatry Res; 1989 May; 28(2):153-9. PubMed ID: 2568651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic augmentation with alprazolam: clinical effects and pharmacokinetic correlates.
    Douyon R; Angrist B; Peselow E; Cooper T; Rotrosen J
    Am J Psychiatry; 1989 Feb; 146(2):231-4. PubMed ID: 2563211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluphenazine treatment of DSM-III-R male schizophrenic patients among the Xhosa.
    Landmark J; Merskey H; Cernovsky ZZ
    Can J Psychiatry; 1994 May; 39(4):219-22. PubMed ID: 8044729
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia.
    Marder SR; Wirshing WC; Van Putten T; Mintz J; McKenzie J; Johnston-Cronk K; Lebell M; Liberman RP
    Arch Gen Psychiatry; 1994 Apr; 51(4):280-7. PubMed ID: 8161288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacotherapy of impaired affect in recovering schizophrenic patients.
    Hogarty GE; McEvoy JP; Ulrich RF; DiBarry AL; Bartone P; Cooley S; Hammill K; Carter M; Munetz MR; Perel J
    Arch Gen Psychiatry; 1995 Jan; 52(1):29. PubMed ID: 7811160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
    Jain RC; Ananth JV; Lehmann HE; Ban TA
    Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
    [No Abstract]   [Full Text] [Related]  

  • 39. Early hospital experience with fluphenazine decanoate.
    Small JG; Kellams J
    Dis Nerv Syst; 1974 Oct; 35(10):453-6. PubMed ID: 17894058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depot fluphenazine for schizophrenia.
    Adams CE; Eisenbruch M
    Cochrane Database Syst Rev; 2000; (2):CD000307. PubMed ID: 10796340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.